FDA stiff-arms Regeneron's bid for more convenient—and competitive—Eylea dosing

13th August 2018 Uncategorised 0

Regeneron, which was thinking its blockbuster eye drug Eylea would extend its market dominance with a new 12-week dosing schedule for some patients, is having to think twice. The FDA has interrupted those plans with delivery of a CRL.

More: FDA stiff-arms Regeneron's bid for more convenient—and competitive—Eylea dosing
Source: fierce